Literature DB >> 24635348

Use of self-controlled designs in pharmacoepidemiology.

J Hallas1, A Pottegård.   

Abstract

Self-controlled observational study designs, such as the case-crossover design and the self-controlled case series, are reviewed, and their respective rationale, strengths and limitations are compared. Although no single design is generally superior to the others, they share the trait of being robust towards confounders that are stable over time. The self-controlled designs can be particularly useful when using secondary healthcare data for pharmacoepidemiological research and might be useful in screening for adverse drug effects. The main limitations of self-controlled designs are that they are amenable only to transient effects; some may be inefficient with long-term exposure; and they may be sensitive towards trends in exposure.
© 2014 The Association for the Publication of the Journal of Internal Medicine.

Keywords:  adverse drug effects; design; epidemiology; methods

Mesh:

Year:  2014        PMID: 24635348     DOI: 10.1111/joim.12186

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  31 in total

Review 1.  Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies.

Authors:  Edward Chia-Cheng Lai; Nicole Pratt; Cheng-Yang Hsieh; Swu-Jane Lin; Anton Pottegård; Elizabeth E Roughead; Yea-Huei Kao Yang; Jesper Hallas
Journal:  Eur J Epidemiol       Date:  2017-07-11       Impact factor: 8.082

2.  Identifying signals of interest when screening for drug-outcome associations in health care data.

Authors:  Anton Pottegård; Jesper Hallas; Shirley V Wang; Joshua J Gagne
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

Review 3.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

4.  Quantitative Bias Analysis in Regulatory Settings.

Authors:  Timothy L Lash; Matthew P Fox; Darryl Cooney; Yun Lu; Richard A Forshee
Journal:  Am J Public Health       Date:  2016-05-19       Impact factor: 9.308

5.  Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations.

Authors:  Jesper Hallas; Shirley V Wang; Joshua J Gagne; Sebastian Schneeweiss; Nicole Pratt; Anton Pottegård
Journal:  Eur J Epidemiol       Date:  2018-03-31       Impact factor: 8.082

6.  Using the Symmetry Analysis Design to Screen for Adverse Effects of Non-vitamin K Antagonist Oral Anticoagulants.

Authors:  Maja Hellfritzsch; Lotte Rasmussen; Jesper Hallas; Anton Pottegård
Journal:  Drug Saf       Date:  2018-07       Impact factor: 5.606

7.  Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting.

Authors:  Amy Peacock; Briony Larance; Raimondo Bruno; Sallie-Anne Pearson; Nicholas A Buckley; Michael Farrell; Louisa Degenhardt
Journal:  Addiction       Date:  2018-09-07       Impact factor: 6.526

8.  Cardiovascular drugs and erectile dysfunction - a symmetry analysis.

Authors:  Lotte Rasmussen; Jesper Hallas; Kenneth Grønkjaer Madsen; Anton Pottegård
Journal:  Br J Clin Pharmacol       Date:  2015-07-28       Impact factor: 4.335

9.  Data Resource Profile: The Danish National Prescription Registry.

Authors:  Anton Pottegård; Sigrun Alba Johannesdottir Schmidt; Helle Wallach-Kildemoes; Henrik Toft Sørensen; Jesper Hallas; Morten Schmidt
Journal:  Int J Epidemiol       Date:  2017-06-01       Impact factor: 7.196

Review 10.  Analytic and Data Sharing Options in Real-World Multidatabase Studies of Comparative Effectiveness and Safety of Medical Products.

Authors:  Sengwee Toh
Journal:  Clin Pharmacol Ther       Date:  2020-01-24       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.